[Role of metadoxyl in the treatment of the hepatotoxic effects of cytostatics].
Safonova
S A
SA
Gershanovich
M L
ML
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002648:Child; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008099:Liver / Q000187:drug effects*; D017093:Liver Failure / Q000139:chemically induced* / Q000517:prevention & control*; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D020011:Protective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D011736:Pyridoxine / Q000008:administration & dosage / Q000627:therapeutic use*; D011761:Pyrrolidonecarboxylic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D004338:Drug Combinations; D020011:Protective Agents; C037845:metadoxine; D011736:Pyridoxine; D011761:Pyrrolidonecarboxylic Acid